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Abstract. Invasive pneumococcal disease (IPD) has high morbidity 
and mortality worldwide. The overall incidence of IPD in Catalonia 
in 2005-2009 was 16.6 per 100,000 persons-year, 66.4 in children 
aged < 2 years and 50.7 in children aged 2-4 years. 7-valent 
pneumococcal conjugate vaccine (PCV7) coverage in Catalonia is 
intermediate. A prospective matched case-control study in children 
aged 3-59 months treated at two hospitals in Catalonia during 2007-
2009 was performed. Potential risk factors for IPD and PCV7 
effectiveness in preventing IPD were investigated. 293 cases and 
785 controls were included. Attendance at daycare or school was a 
risk factor for IPD (aOR 3.07, 95% CI 1.97-4.78) and the 
effectiveness of PCV7 against vaccine serotypes was 93.7% (95% 
CI 51.8 -99.2). 
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Introduction 
 
 Invasive pneumococcal disease (IPD) causes high morbidity and 
mortality worldwide. The estimated burden of IPD in children aged <5 
years is 14.5 million annual episodes, and about 800,000 deaths, mostly in 
developing countries [1]. In developed countries, children aged <2 years, 
older adults and people with immune deficiency are at increased risk of 
IPD [2].  
 The 7-valent pneumococcal conjugate vaccine (PCV7) including seven 
of the 90 Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F 
and 23F) was marketed in 2000 in the US and 2001 in Europe. Studies of 
PCV7 effectiveness corroborated previous efficacy results [3-5]. The        
10-valent pneumococcal conjugate vaccine (PCV10) was marketed at the 
end of 2009 and the 13-valent conjugate pneumococcal vaccine (PCV13) 
in 2010. PCV13 replaced PCV7 and contains PCV7 serotypes plus 
serotypes 1, 3, 5, 6A, 7F and 19A. PCV10 contains the PCV7 serotypes 
plus serotypes 1, 5, and 7F. The decline in PCV7 serotypes caused a 
decrease in IPD incidence which, however, then increased slightly due to 
the emergence of serotype 19A [6].  
 During 2005-2009 in Catalonia, the overall incidence of IPD was 16.6 
cases per 100,000 persons-year. The highest incidence was in children aged 
<2 years (66.4 cases per 100,000 persons-year), children aged 2-4 years 
(50.7 cases per 100,000 persons-year), and persons aged ≥ 65 years (35.5 
cases per 100,000 persons-year). In this period, PCV7 serotypes accounted 
for 17.5% of cases, PCV10 serotypes for 48.6%, and PCV13 serotypes for 
69.8% [7]. In children aged <2 years, in 2008, PCV7 serotypes accounted for 
19.4% of cases, PCV10 serotypes for 41.8% and PCV13 serotypes for 77.6% 
[8]. PCV7 is not included in the Spanish routine vaccination schedule 
(except in the Autonomous Community of Madrid during 2006-2012 and in 
Galicia in January 2012), although it was administered in children aged <5 
years with risk medical conditions [9] following international 
recommendations [10].The Spanish Association of Pediatrics recommended 
the administration of the vaccine in 2003 [11]. PCV7 vaccination coverage 
in Catalonia in 2007-2009 was around 50% [12]. 
 In Spain, where there is widespread use of antibiotics [13], an increase 
in IPD cases caused by multiresistant clones expressing non-vaccine 
serotypes [14] was detected. This made it necessary to determine the risk 
factors associated with these cases.  
 From the public health perspective it is important to determine the 
factors related to the host (age, genetic factors, risk medical conditions), 
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socio-demographic factors (daycare, social class) and clinical factors 
possibly associated with IPD [15-17].  
  The objectives of this study were to investigate risk factors for IPD 
and for non-penicillin susceptible strains, to evaluate factors associated 
with PCV7 vaccination and to investigate the effectiveness of PCV7 
against IPD caused by vaccine serotypes in children aged <5 years in 
Catalonia.  
  
1. Methods 
  
Study design 
  
 We made a matched case-control study in 2007-2009 in two pediatric 
hospitals in Barcelona (Sant Joan de Deu Hospital and Valle Hebron 
Hospital). A case was defined as a patient aged <5 years attended with 
clinical signs of infection and microbiological confirmation (culture or 
detection of Streptococcus pneumoniae DNA by PCR) in normally sterile 
fluid [12]. 
 Serotyping was made by Quellung reaction or PCR [18, 19]. 
Susceptibility to penicillin was studied by agar dilution (defined according 
to the 2008 Clinical Laboratory Standards Institute cutoffs) [20]. Controls 
were patients aged 3-59 months treated by the two hospitals for other 
reasons than infectious diseases. Three controls per case matched by sex, 
age (<12 m: +/- 3m; 12-23 m: +/- 6m; 24-59 m: +/-12m), date of 
hospitalization and underlying disease (when present) were selected. Cases 
and controls in whom the PCV7 vaccine status was unknown, and cases in 
whom the serotype could not be determined, were excluded.  
 The clinical variables studied were age, sex, and medical risk 
condition. In cases, signs and symptoms, ICU admission, evolution, 
serotype and penicillin susceptibility were collected. Daycare or school 
attendance, home exposure to smoking (number of cigarettes/day), number 
of cohabitants, age of siblings, breastfeeding in the previous month, 
antibiotics in the previous month, and respiratory infection in the previous 
month were collected using a single questionnaire. The parents‟ 
socioeconomic status according to the British occupation classification was 
collected [21]. 
 PCV7 vaccination (date and number of doses) was collected through 
the vaccination card, medical record, or health center record. A vaccinated 
patient defined as vaccine reception ≥ 15 days before symptom onset (if 
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any) or hospital admission date (controls) and a fully vaccinated patient as 
reception of the recommended doses according to age. 
 The minimum sample size was calculated using Schlesselman‟s 
criteria [22]. A prevalence of vaccination of 25% in the healthy population 
(data before the start of the study in Catalonia) [23] and a PCV7 
effectiveness against IPD of 80% was assumed. It was assumed that 
vaccine serotypes produce 20% of cases. With an alpha error of 0.05 (two-
tailed), a beta error of 0.20 and three controls per case and analyzing two 
age groups its was estimated that 270 cases and 810 controls were 
required. 
 The vaccine effectiveness (VE) was calculated in cases with vaccine 
serotypes, non-vaccine serotypes, and all serotypes in the 24-59 months 
and 7-23 months age groups. The study was approved by the ethics 
committee of each hospital. 
  
Statistical analysis  
  
 Crude odds ratios (OR) and adjusted odds ratios (aOR) of the 
associations between study variables and PCV7 vaccination (fully 
vaccinated and non-vaccinated) were calculated using unconditional 
multivariate logistic regression for all cases and controls. To study possible 
risk factors and IPD in cases and controls, multivariate conditional logistic 
regression was made and independent variables with a significance of p <0.2 
included. The vaccination history, daycare or school attendance, and 
antibiotic treatment were included in the analysis because of their clinical 
relevance. Unconditional logistic regression was used to calculate the OR 
and aOR of the association between study variables and non-penicillin 
susceptible strains in all cases of IPD. VE was calculated using the formula 
VE = (1- aOR) x 100. All analyses were made using SPSS version 18 (SPSS 
Inc. USA). 
  
2. Results 
 
Risk factors associated with IPD 
  
 We included 293 cases and 785 controls [12]. Over 60% of cases were 
confirmed by PCR. Pneumonia with empyema was the most frequent 
clinical form (64.5%), followed by uncomplicated pneumonia (15.7%). 
Non- PCV7 serotypes accounted for 91.1% of cases, PCV10 serotypes for 
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39.2% and PCV13 serotypes for 70%. The most common serotypes were 1 
(21.2%), 19A (16.0%), 3 (12.6%) and 7F/A (6.8%). Diseases predisposing 
to IPD were present in 1.4% of cases (n = 4) (immunosuppression in 2 
cases, diabetes mellitus in 1 and pulmonary emphysema in 1 case). In all 
four cases, IPD was caused by non-PCV7 serotypes and had received                     
≥ 1 PCV7 doses. The case fatality rate was 1% (3 cases, all with meningitis 
and due to serotypes 6A, 7F/A, and 23F). Of controls, 47.1%                                           
were correctly vaccinated with PCV7, while 58.7% had received ≥ 1                 
doses. 
 Daycare or school attendance (aOR 3.07, 95% CI 1.97-4.78) and > 4 
cohabitants (aOR 2.0, 95% CI 1.37-2. 90) were global risk factors for IPD. 
Daycare or school attendance were risk factors for IPD in the 12-23 
months (aOR 4.89, 95% CI 2.25-10.25) and 24-59 months (aOR 2.82, 95% 
CI 1.13-7.05) age groups. Other risk factors were > 4 cohabitants in the         
24-59 months age group (aOR 2.04, 95% CI 1.27-3.28) and previous 
respiratory infection in the 12-23 months age group (aOR 1.98, 95% CI 
1.02-3.86). 
 Protective factors against IPD were reception of ≥ 1 doses of PCV7 in 
the 3-11 months (aOR 0.35, 95% CI 0.14-0.86) and 12-23 months (aOR 
0.47, 95% CI 0.24-0.94) age groups, but not in the 24-59 months age group 
(aOR 1.01, 95% CI 0.67-1.52). Children aged 24-59 months who had 
received antibiotic treatment in the previous month had greater protection 
against IPD (aOR 0.51, 95% CI 0.29-0.89). Other variables (having 
siblings aged <5 years, breastfeeding in the previous month and exposure 
to smoking in the home were not risk factors for IPD. 
 Serotype 1 was associated with the 24-59 months age group, 
pneumonia, pneumonia with empyema, and daycare or school attendance. 
All IPD cases due to serotype 1 were penicillin susceptible (Table 1). 
Serotype 19A was associated with age <24 months, pneumonia with 
empyema, previous respiratory infection and non-penicillin susceptible 
strains. Serotype 3 was associated with pneumonia and empyema, and 
reception of ≥1 dose of PCV7. Serotype 7F was not associated with any o f 
the variables studied [24]. 
 Penicillin susceptibility was analyzed in all strains (115): 40 (34.8%) 
were not susceptible. Children aged 24-59 months had a lower risk of non-
penicillin susceptible IPD than those aged 3-23 months. Antibiotic 
treatment during the previous month and serotype 19A were risk factors 
for non-penicillin susceptible IPD [12] (Table 2). 
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Table 1. IPD risk factors associated with serotypes in children aged 3-59 months. 
  
 
Serotype 1  
(n=62) % 
Others  
(n=231) % 
aOR (95%CI) 
Age    
 3-23 months 8.1  47.6  Reference 
 24-59 months 91.9  5.4  7.70 (2.70-21.98)  
Pneumonia 100.0 74.9 --- 
Empyema 75.8 61.5 2.57 (1.33-4.96) 
Daycare or school  
attendance  
93.3 78.1 3.55 (1.21-10.38) 
Non-penicillin 
susceptible 
0.0 100.0 ---- 
 
Serotype 19A  
(n=47) % 
Others 
(n=246) % 
aOR (95% CI) 
Age    
3-23 months 70.2 33.3  Reference 
24-59 months 29.8  66.7  0.19 (0.09-0.41)  
Empyema 57.4 65.9 7.80 (2.91-20.86) 
Respiratory 
infection 
65.1 44.6 2.26 (1.03-4.94) 
Non-penicillin 
susceptible 
60.0 25.9 1.89 (1.13-3.16) 
 
Serotype 3  
 
(n=37) % 
 
Others 
(n=256) % 
aOR (95% C I) 
Empyema 75.7 62.9 3.01 (1.22-7.43) 
Vaccination status    
Non vaccinated 24.3 50.0 Reference 
Vaccinated 73.0 41.4 4.87 (2.05-11.59) 
 
 
Adjusted odds ratio (95%CI) for conditional logistic regression model, which included 
vaccination with≥1 dose of PCV7, attending daycare or school and antibiotics prescribed within 
30 days before the onset of clinical symptoms. 
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Table 2. Factors associated with IPD penicillin-nonsusceptible in children aged 3-59 
months. 
  
Variables 
IPD non 
susceptible 
(N = 40) 
IPD 
susceptible 
(N = 75) OR (95% CI)  aOR (95% CI)  
N 
 
% N 
 
% 
Sex (male)  25  62.5  41  54.7  1.38 (0.63-3.03)  1.27 (0.51-3.15)  
Age             
3-23 months 3. 4  85.0  33  44.0  Reference  Reference  
24-59 months  6  15.0  42  56.0  0.14 (0.05-0.37)  0.14 (0.04-0.44)  
≥1 dose PCV7  19  47.5  40  53.3  0.79 (0.37-1.71) 0.74 (0.27-1.51)  
Daycare or 
school 
attendance 
27  71.1  61  82.4  0.52 (0.21-1.31) 0.44 (0.16-1.23)  
Antibiotic 
treatment  
10  26.3  5  6.8  4.93 (1.54-15.72) 4.30 (1.09-16.94)  
Respiratory 
infection 
  
22  57.9  36  48.6  1.45 (0.66-3.19) 1.24 (0.48-3.22) 
Clinical form             
Meningitis  9  22.5  12  16.0  1.52 (0.58-4.00)  1.21 (0.40-3.69) 
Pneumonia  18  45.0  47  62.6  0.49 (0.22-1.06) 0.70 (0.25-1.97)  
Bacteremia  11  27.5  11  14.7  2.21 (0.86-5.67) 1.28 (0.45-3.69)  
Other clinical 2  5.0  5  6.7  0.74 (0.14-3.98) 0.48 (0.08-2.81)  
Serotype             
1  0  0.0  28  37.3  Reference  Reference  
19A  18  45.0  12  16.0  4.29 (1.79-10.32)  3.58 (1.28-10.05)  
3  1  2.5  5  6.7  0.36 (0.04-3.18)  0.40 (0.04-4.49)  
7F/A  0  0  10  13.3  ---- ---- 
        
   
         Adjusted OR (95% CI) for unconditional logistic regression model, which included  
  vaccination with  ≥1 dose of PCV7, attending daycare or school and antibiotics  
  prescribed within 30 days before the onset of clinical symptoms. 
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Factors associated with PCV7 
  
 Children attending daycare were more frequently vaccinated than 
children who did not. Children aged 24-59 months were less frequently 
vaccinated than children below this age. Children with > 4 cohabitants and 
those with a lower social class were less frequently vaccinated [12]             
(Table 3). 
  
Table 3. Factors associated with 7-valent conjugate pneumococcal vaccination in 
children 3-59 months. 
  
Variables 
Fully vaccinated 
(N = 501) 
Non-vaccinated  
(n = 460) 
OR (95% CI) aOR (95% CI) 
N % N % 
Age         
 
  
3-11 months 67  13.4  64  13.9  Reference Reference  
12-23 months 148  29.5  112  24.3  1.26 (0.83-1.92) 0.98 (0.62-1.56)  
24-59 months 286  57.1  284  61.7  0.96 (0.66-1.41) 0.54 (0.33-0.88)  
Daycare or school  
attendance  
381  76.4  310 68.3 1.50 (1.13-2.00) 1.70 (1.12-2.56)  
Breastfeeding  30  6.1  39 8.7 0.68 (0.41-1.11) 0.71 (0.41-1.22)  
Exposure to  
smoking  
        
 
  
0 cig/day  285  61.3  247 58.8 Reference Reference  
1-19 cig/day  84  18.1  68 16.2 1.07 (0.74-1.54) 1.31 (0.87-1.97)  
≥20 cig/day  99  20.6  105 25.0 0.79 (0.57-1.10) 0.88 (0.61-1.27)  
> 4 cohabitants  58  11.8  106  23.5  0.44 (0.31-0.62) 0.58 (0.39-0.86)  
Siblings <5 years  135  27.4  126  27.9  0.98 (0.73-1.30) 1.17 (0.83-1.65)  
Social class          
 
  
I-III  282  68.0  167  46.4  Reference Reference  
IV-V  133  32.0  193  53.6  0.41 (0.30-0.55) 0.46 (0.34-0.62)  
Medical risk   
condition  
4  1.0  4  0.87  1.15 (0.31-4.31) 0.99 (0.24-4.02)  
     
    
              
                     
 
                Adjusted OR (95% CI) for unconditional logistic regression model. 
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Vaccine effectiveness 
   
 The VE of complete PCV7 vaccination was 93.7% (Table 4). VE was 
higher in children aged 7-23 months than those aged 24-59 months. In this 
age group no significant differences were found because the statistical power 
of the study was low (40%) since few cases caused by vaccine serotypes 
were found. No protection was found against IPD caused by non-vaccine 
serotypes or all serotypes [25]. 
 
Table 4. Effectiveness of 7-valent pneumococcal vaccine in fully vaccinated children 
aged 7-59 months. 
  
  
Serotype 
Cases 
 
Controls Crude 
vaccination  
effectiveness 
 
Adjusted 
vaccination  
effectiveness 
Vaccinated*/ N  
(%) 
Vaccinated*/ N  
(%) 
(95% CI) 
 
(95% CI) 
  
 
Vaccine 
serotypes 
4/23 
(17.4) 
36/61 
(59.0) 
93.8% 
(51.9-99.2) 
93.7% 
(51.8-99.2) 
 7-23 
months 
1/14 
(7.1) 
24/40 
(60.0) 
92.3% 
(38.1-99.0) 
92.5% 
(39.3-99.1) 
 24-59 
months 
3/9 
(33.3) 
12/21 
(57.1) 
79.2% 
(-84.7 to 97.7) 
79.4% 
(-84.0 to 97.7) 
Non 
vaccine 
serotypes 
120/228 
(52.6) 
315/597 
(52.8) 
-8.0% 
(-56.4 to 25.4) 
-10.9% 
(-65.6 to 25.7) 
All 
serotypes 
124/251 
(49.6) 
351/658 
(53.3) 
16.1% 
(-13.5 to 37.9) 
13.2% 
(-20.7 to 37.6) 
 
 
*Incompletely vaccinated children were excluded from the analysis. 
 Adjusted using conditional logistic regression for attendance at daycare or school (all    
serotypes and non-vaccine serotypes), cohabitants (all serotypes and non-vaccine serotypes) and 
age (all serotypes, vaccine serotypes in all age groups and non-vaccine serotypes). 
  
3. Discussion 
   
 In children aged <5 years, PCV7 serotypes caused 8.9% of cases of IPD 
in 2007-2009: 39.2% and 70% of cases were caused by PCV10 serotypes 
and PCV13 serotypes, respectively. The most common serotypes were all 
PCV13 serotypes: 1 (21.2%), 19A (16.0%), 3 (12.6%) and 7F/A (6.8%). The 
differences in the distribution of serotypes in children aged <5 years 
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compared with a 2005-2009 study in 50 Catalan hospitals [7] may be 
explained, at least in part, by the diagnosis of 60.8% by PCR in the present 
study compared with 19.1% in the previous study. In addition, the cases 
studied were attended in two reference centers and, therefore, the IPD cases 
may have been more severe: the serotypes involved could also have 
influenced this distribution. Gutierrez et al. [26] found that serotype 19A 
was predominant in children aged <5 years in the Autonomous Community 
of Madrid in 2007, after the inclusion of PCV7 in the routine vaccination 
schedule, whereas in our study it was serotype 1. 
 The most frequent clinical forms were pneumonia with empyema 
(64.5%), pneumonia without empyema (15.7%), meningitis (9.6%), non-
focal bacteremia (7.5%), and other clinical forms (2.7%). The increase in 
IPD due to serotype 1 was caused primarily by the emergence of clone 306, 
which is related to this serotype and has caused various cases of pneumonia 
with empyema [14]. Other studies have shown an increase in empyema in 
children, especially after the introduction of PCV7. Calbo et al. [27], in 
Barcelona, found that the rate of pneumonia with empyema increased from 
1.7 cases per 100,000 persons-year in the pre-vaccine era (1999-2001) to 8.5 
cases in the vaccine era (2002-2004). Obando et al. [28] found a 13-fold 
increase in the incidence in Seville and Malaga and a 6-fold increase in 
Barcelona, after comparing data from 1998 and 2006. A lower increase in 
empyema in children was observed in the US [29]. In England, Koshy et al. 
[30] found an increase in empyema before the introduction of PCV7, but 
comparison of the results before and after the introduction of the vaccine 
showed the increase was not significant. 
 We found an association between daycare or school attendance and IPD, 
as described in other studies in the pre-vaccine [31-34] and vaccine eras 
[35].This association was observed in children aged 12-59 months, but not in 
those aged <12 months, possibly due to the small number of cases studied in 
this age group. In a semi-closed environment (such as a daycare center) there 
is a greater possibility of contact with colonized children and, therefore, 
greater exposure to S. pneumoniae. Most children attending daycare or 
school were correctly vaccinated with PCV7 for their age, but had a higher 
risk of IPD due to PCV7 serotypes than those not attending. 
 Having siblings aged <5 years was not a risk factor for IPD. A 1986-
1989 Finnish case-control study by Takala et al. [34] in 248 cases aged <15 
years found that having siblings aged <7 years was associated with IPD in 
children aged ≥ 2 years but not in those aged < 2 years. A 1980-2005 Danish 
case-control study by Hjuler et al. [32] in 1,381 cases aged <5 years 
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concluded that children aged <5 months with older siblings had higher risk 
of IPD than those without, while having older siblings was a protective 
factor for IPD in children 6-23 months, possibly due to natural immunization 
against IPD. In our study, PCV7 administration could be reducing the carrier 
status of siblings, as suggested by Givon-Lavi et al [32], while daycare 
attendance could have a greater influence than having siblings aged <5 
years. 
 We found an association between cohabitation with ≥ 4 people and IPD 
only in children aged 24-59 months. The lack of association in the 3-11 
months and 12-23 months age groups may have been due to the low number 
of cases in these groups.  
 A US study by Levine et al. [31] in the pre-vaccine era found no 
association between antibiotic treatment in the previous 3 months and IPD 
caused by strains with an MIC ≥2 mg/mL. In our study, children aged <2 
years, serotype 19A and treatment with antibiotics during the previous 
month were associated with non-penicillin susceptible serotypes, reinforcing 
the importance of correct antibiotic prescription to prevent the spread of 
penicillin-resistant clones. We found a negative association for antibiotic 
treatment in the previous month in children 24-59 months once possible 
confounders, such as a history of vaccination and daycare or school 
attendance were controlled for. This may be related to the large number of 
cases of IPD due to penicillin-sensitive serotype 1 [14]. 
 Viral respiratory infection in the month prior to IPD has been described 
as a risk factor for developing the disease [37, 38]. Respiratory viruses alter 
endothelial cells, promoting bacterial adherence [39]. In addition, there is 
less clearance of S. pneumoniae in previously colonized airways [40], which 
favors the spread of pneumococci in normally sterile areas. We only found 
this association in children aged 12-23 months. Other factors may be 
involved, such as the etiologic agent causing the viral infection or the child‟s 
immune system [41]. 
 In our study breastfeeding had no protective effect against IPD, as did a 
study by Pilishvili et al. [35] after the introduction of PCV7. However, a 
study by Levine et al. [31] before the introduction of PCV7 found a 
protective effect of breastfeeding against IPD. This protective effect due to 
the transfer of antibodies from mother to child may be lower than the 
protective effect and the herd immunity provided by PCV7. 
 We found no association between parental smoking and IPD, similar to 
other studies [34, 42, 43]. However, studies by O'Dempsey et al. [44] in the 
pre-vaccine era and Pilishvili et al. [35] in the vaccine era found an 
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association between IPD and parental smoking. A meta-analysis of 30 case-
control studies found no association between high exposure to smoking and 
IPD in children [45].  
 Serotype 1 was associated with the 24-59 months age group, pneumonia, 
and pneumonia with empyema. All cases due to serotype 1 caused 
pneumonia and were penicillin-susceptible. As noted, the increase in IPD 
due to serotype 1 was mainly caused by the ST306 clone [14]. Other studies 
[26] have found associations between serotypes 1, 3 and 7F and pneumonia 
in children aged <5 years or between serotype 1 and pneumonia with 
empyema in persons aged <18 years [46]. Serotype 1, unlike other serotypes, 
has been associated with daycare or school attendance. The presence of 
clone ST306 strains of serotype 1 in our community is a possible explanation 
[14]. This clone is penicillin-susceptible and can produce outbreaks in high-
density populations such as daycare or schools [47]. Daycare or school 
attendance helps maintain the circulation of pneumococci and increases 
carrier status [48, 49], which may favor the development of micro-epidemics 
[47].  
 Serotype 19A was associated with age <2 years and with pneumonia 
with empyema. The association between serotype 1 and the 24-59 months 
age group and between serotype 19A and children aged <2 years has been 
found by other authors [26, 46]. Serotype 19A has been described in a large 
percentage of carriers, with different clonal expressions [14, 50, 51] and has 
an elevated capacity to produce IPD. In addition, it was associated with 
respiratory infection in the month prior to IPD. This may explain, at least in 
part, why an imbalance in the ability of host defense against respiratory 
infection [50,52] and tissue damage caused by the virus, favors the invasion 
of cells and produces IPD more easily than other serotypes. We found an 
association between serotype 19A and non-susceptibility to penicillin. The 
association of non-penicillin susceptible strains with serotype 19A may be 
explained by the introduction of the multidrug-resistant clonal complex 
ST320 expressed by serotype 19A [14]. The fact that these strains are 
associated with taking antibiotics in the month prior to IPD reinforces the 
need to recommend correct antibiotic administration to patients to prevent 
the emergence of resistant strains. This is especially relevant in our setting, 
where there is a high consumption of antibiotics [13]. 
 Serotype 3 was the third most frequent serotype in children aged <5 
years and was associated with pneumonia with empyema and receiving ≥1 
dose of PCV7. Most cases due to serotype 3 were diagnosed by PCR. When 
PCR is not used, few cases of serotype 3 are observed as it is more difficult 
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to grow in cultures [19]. A large percentage of carriers present serotype 3, 
which has low invasive potential [53] but produces complications such as 
parapneumonic empyema [28], necrotizing pneumonia [54] and hemolytic 
uremic syndrome, [55] with a high case fatality rate [56]. We found an 
association between serotype 3 and PCV7 vaccination. Bender et al. [54] 
found that a large percentage of children with necrotizing pneumonia due to 
serotype 3 had received ≥1 dose of PCV7 compared with children with 
pneumonia caused by other serotypes, although the differences were not 
significant. PCV7 exercises natural selection in the ecological niche of the 
nasopharynx and decreases the percentage of carriers of vaccine serotypes, 
which has been described as one of the main factors responsible for the 
replacement of PCV7 serotypes by non-PCV7 serotypes [57]. Other authors 
have described an association between PCV7 administration and serotype 
19A [26, 58]. We found an intermediate PCV7 coverage and, therefore, the 
results may differ in regions with high coverages.  
 Serotype 7F/A was the fourth most frequently observed in children aged 
<5 years but no association with the factors studied was found, possibly due 
to the number of cases. Although the presentation included all clinical forms, 
the most frequent was pneumonia. In this serotype 1/20 cases (5%) resulted 
in death. Rückinger et al. [56] found the highest case fatality rate for 
serotype 7F (14.8%), serotype 3 (8.3%), and serotype 23F (8.3%). Serotype 
7F has also emerged after the introduction of PCV7 in children. Some 
studies suggest it is a serotype with high invasive potential that acts as a 
primary pathogen, like serotype 1 [53]. In our study, serotype 7F/A strains 
studied were penicillin-susceptible, as observed by Aguiar et al. [46].  
 In Catalonia, the strategy of vaccinating with PCV7 vaccination of 
children aged <5 years with risk diseases and private vaccination by parents 
according to the AEP recommendations explains why 47.1% of controls 
were correctly vaccinated according to age and 58.7% had received at ≥1 
vaccine dose. The vaccination coverages found in our study were similar to 
those of other Spanish studies [27, 57] but lower than those found in other 
countries that include PCV7 in the routine immunization schedule [59-61]. 
 In our study, children attending daycare or school had received PCV7 
more frequently than those who did not, possibly due to pediatricians‟ 
recommendations [11, 62]. Children aged 24-59 months and children living 
with > 4 cohabitants were less frequently vaccinated than those aged <2 
years and those cohabiting with ≤ 4 people. In addition, children of low 
social class were less frequently vaccinated than those of high social class, 
possibly due to lesser parental purchasing power. 
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 The case fatality rate in children aged <5 years was 1%, slightly lower 
than that observed by Ingels et al. [63]. However, IPD preferably presents in 
people with risk medical conditions [15]. Pilishvili et al. [35], in the US, 
found that 11.3% of children aged <5 years with IPD had risk medical 
conditions. In our study, only four cases (1.4%) had diseases predisposing to 
IPD. 
 The study of VE is of great interest in public health. We found that 
complete PCV7 vaccination had a VE of 93.7% (95% CI 51.8% -99.2%) in 
avoiding cases of IPD caused by vaccine serotypes. There were differences 
in VE between age groups. In the 7-23 months age group, PCV7 was 
effective (VE 92.5%; 95% CI 39.3% -99.1%), while in children aged 24-59 
months there was a nonsignificant trend to protection (VE 79.4%; 95% CI -
84.0% to 97.7%). However, the statistical power of the study in this age 
group was only 40.5%, due to the low number of subjects included (10 cases 
of IPD caused by vaccine serotypes) and the high proportion of serotype 1 
cases. Studies in different regions and countries have shown the 
effectiveness of PCV7. The case-control study by Whitney et al. [4] in the 
US, with 782 cases and 2,512 controls, found a VE for ≥1 doses of PCV7 of 
96% (95% CI 93%-98%) in healthy children and 81% (95% CI 57-92%) in 
children with chronic disease. In Quebec province (Canada), Deceuninck et 
al. [5] conducted a study with 180 cases and 897 controls, and obtained an 
VE for IPD caused by vaccine serotypes of 92% (95% CI 83%-96%) and for 
IPD caused by any serotype of 60% (95% CI 38%-75%). Barricarte et al. 
[64], in Navarre, with 85 cases and 425 controls, found a VE for ≥1 doses of 
88% (95% CI: 9%-98%) for vaccine serotypes. Mahon et al. [65] in the US, 
found a VE of 90.5% (95% CI 17.7%-98.9%) for complete vaccination 
(three doses plus booster). In children aged <7 months old, the VE was 
76.6% (95% CI 50.4%-88.9%) when three doses were administered and 
70.5% (95% CI 28.8%-87.9%) in children aged <5 months with two doses. 
No effectiveness was shown for one vaccine dose in children aged <3 
months (VE 38.8%; 95% CI: -79.7% to 79.1%). The results of the schedule 
started in the second year of life were inconclusive, possibly due to the small 
sample number.  
 Rückinger et al. [66] in a German indirect cohort study found a VE for 
complete vaccination of 94.6% (95% CI 69.7%-99.5%). VE for ≥1 doses of 
PCV7 was 88.3% (95% CI 64.0%-96.6%) and VE for one, two and three 
doses in the first 7 months were 78.1% (95% CI 3.4%-96.1%), 89.8% (95% 
CI 20.6%-100%) and 94.6% (95% CI 69.7%-99.5%), respectively.  
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 Our study, like all observational studies, has strengths and limitations. 
One strength is the study design and methodology, which minimized 
potential selection and information bias. To minimize selection bias, cases 
and controls were matched using variables such as age, sex, underlying 
disease, the hospital and the date of hospitalization. Social class was not 
used for matching, but no significant differences between cases and controls 
were found.  
 Possible information bias was minimized by collecting information on 
the vaccination status from individual health records (vaccination card, 
medical record or health center records) with information recorded prior to 
the study. Sociodemographic and epidemiological variables were collected 
using a single questionnaire for cases and controls administered to parents. 
Moreover, the use of PCR and culture as diagnostic techniques increased the 
ability to detect IPD, as PCR provided the most cases. The low proportion of 
cases caused by vaccine serotypes (8.9%) made it difficult to obtain 
significant results in the 24-59 months age group, but this could not have 
been predicted beforehand. 
 Finally, we made a conditional logistic regression analysis including 
variables whose clinical relevance could have had a confounding effect, such 
vaccination, daycare or school attendance, and antibiotic treatment, and the 
variables in the bivariate analysis associated with the dependent variable. 
Therefore, although some residual confusion cannot be ruled out, the results 
can be considered as reasonably valid.  
  
4. Conclusions 
  
 In children aged <5 years, PCV7, PCV10 and PCV13 vaccine serotypes 
represented 8.9%, 39.2% and 70.0% of cases, respectively. The most 
common serotypes were: 1, 19A, 3 and 7F/A. Molecular PCR allowed 
identification of IPD cases not identified by conventional culture. This was 
particularly relevant in IPD caused by serotypes 1 and 3.  Serotype 1 was 
associated with the 2-4 years age group, pneumonia with empyema and 
daycare or school attendance. Serotype 19A was associated with age < 2 
years, pneumonia with empyema, previous respiratory infection, and non-
penicillin susceptible strains. 
 Children attending daycare had the highest PCV7 vaccination coverage 
(76.4%) and those with a lower social class the lowest coverage (32.0%). 
PCV7 vaccine effectiveness was very high in children aged 7-59 months 
(93.7%; 95% CI 51.8%-99.2%). In children aged 24-59 months VE was 
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lower (79.4%; 95% CI -84.0% to 97.7%) than in children aged 7-23 months 
(92.5%; 95% CI 39.3%-99.1%). 
 Accurate monitoring that allows the identification of emerging                   
strains and patterns of antibiotic sensitivity patterns is necessary to prevent 
IPD. 
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